ʻO Daclatasvir Dihydrochloride
wehewehe
ʻO Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) he mea ikaika a hana waha.HCV NS5A pūmuamea hoʻopaneʻe meEC50s laula o 9-146 pM nomau genotypes HCV replicon. ʻO Daclatasvir dihydrochloride kekahiʻO ka anion organik e lawe ana i ka polypeptide 1B (OATP1B)aOATP1B3mea hoʻopaneʻe meIC50s o 1.5 µM a me 3.27 µM.
IC50& Pahuhopu
EC50: 50 pM (HCV replicon genotype 1a), 9 pM (HCV replicon genotype 1b), 71 pM (HCV replicon genotype 2a), 146 pM (HCV replicon genotype 3a), 12 pM (HCV replicon genotype 4a) a me HCV replicon genotype 4a) HCV replicon genotype 5a)[1]
Kd: 8 nM (NS5A33-202) a me 210 nM (NS5A26-202)[2]
IC50: 1.5 µM (OATP1B) a me 3.27 µM (OATP1B3)[3]
In Vitro
Hōʻike ʻo Daclatasvir (BMS-790052) i ka hana paʻa ikaika i nā genotypes i hoʻāʻo ʻia, me EC50mai 9 pM a 146 pM. Kāohi ʻo Daclatasvir i ka HCV replicon genotype 1a, 1b, 2a, 3a, 4a a me 5a me EC5050 pM, 9 pM, 71 pM, 146 pM, 12 pM a me 33 pM. ʻO Daclatasvir kahi mea hoʻopaneʻe ikaika o ka JFH-1 genotype 2a maʻi maʻi infectious e hana hou ana i ka moʻomeheu cell (EC50=28 pM)[1]. Hoʻopili paʻa ʻo Daclatasvir (BMS-790052) iā NS5A33-202 a me NS5A26-202 me Kds o 8 nM a me 210 nM[2].
Waihona
| Pauda | -20°C | 3 makahiki |
| 4°C | 2 makahiki | |
| I ka solvent | -80°C | 6 mahina |
| -20°C | 1 mahina |
Hoao Hoao
| Helu NCT | Kākoʻo | Kūlana | lā hoʻomaka | Māhele |
| NCT03369327 | Teheran University of Medical Sciences|RojanPharma Pharmaceutical Company | ʻO ka maʻi maʻi hepatitis C, pane i ka lāʻau lapaʻau o|Human Immunodeficiency Virus | Ianuali 1, 2017 | Māhele 3 |
| NCT03485846 | R-Pharm|Almedis | Hepatitis C Genotype 1b | Nowemapa 27, 2017 | Māhele 2 |
| NCT01016912 | Bristol-Myers Squibb | Ma'i Hepatitis C | Kekemapa 2009 | Māhele 2 |
| NCT01629732 | Bristol-Myers Squibb | Hepatitis C Virus | Malaki 2013 | Māhele 2 |
| NCT01497834 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Ianuali 2012 | Māhele 3 |
| NCT01973049 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Kekemapa 2013 | Māhele 3 |
| NCT00663208 | Bristol-Myers Squibb | Hepatitis C | Mei 2008 | Māhele 2 |
| NCT02576314 | Ke Keena Imi Kanaka a Ola Ola|Beijing 302 Hospital | Ma'i Hepatitis C mau | Mei 2015 | Māhele 3 |
| NCT02756936 | Ke kikowaena noiʻi maoli, ʻAigupita|Zeta Pharmaceutical Industries | Ola ola | Pepeluali 2016 | Māhele 1 |
| NCT02771405 | National Hepatology & Tropical Medicine Research Institute|Kairo University | ʻO ka maʻi maʻi maʻi C, ka maʻi maʻi|hepatocellular carcinoma | Malaki 2016 | Māhele 3 |
| NCT03706898 | Viriom | HIV-1-infection|Hinoʻino i ka Hepatic | ʻOkakopa 1, 2018 | Māhele 1 |
| NCT02319031 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Pepeluali 2015 | Māhele 3 |
| NCT02124044 | National Institute of Health Clinical Center (CC)|National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb | HIV-HCV | Pepeluali 2014 | Māhele 2 |
| NCT02551861 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Kekemapa 2015 | Māhele 2 |
| NCT00859053 | Bristol-Myers Squibb | Hepatic Insufficiency | Malaki 2009 | Māhele 1 |
| NCT01257204 | Bristol-Myers Squibb | Hepatitis C Virus | Kekemapa 2010 | Māhele 2 |
| NCT03063879 | Teheran University of Medical Science|Ahvaz Jundishapur University of Medical Science|Shiraz University of Medical Science|Hamadan University of Medical Science | ʻO ka maʻi maʻi maʻi C, ka maʻi | | ʻApelila 1, 2017 | Māhele 4 |
| NCT01017575 | Bristol-Myers Squibb | Ma'i Hepatitis C | Kekemapa 2009 | Māhele 2 |
| NCT02865369 | Sang Gyune Kim|Seoul National University Boramae Hospital|Severance Hospital|Inha University Hospital|Korea University|Gachon University Gil Medical Center|Hanyang University Seoul Hospital|Ewha Womans University Mokdong Hospital|Bristol-Myers Squibb|Soonchunhyang University Hospital | Hepatitis C | Kepakemapa 2016 |
|
| NCT04070235 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | ʻO ka maʻi maʻi maʻi C, ka maʻi maʻi | Malaki 29, 2019 | Māhele 2|Mahele 3 |
| NCT03487848 | Bristol-Myers Squibb | Hepatitis C|Ma'i ma'i ma'i ma'i | Mei 18, 2018 | Māhele 2 |
| NCT00904059 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Mei 2009 | Māhele 1 |
| NCT02107365 | ʻO ke Keʻena Lapaʻau Palani no ka Noʻonoʻo Ola a me ka ʻImi Lapaʻau-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | Hepatitis C Virus Genotype 4 Infection | Nowemapa 2013 | Māhele 2 |
| NCT02397395 | ʻO Janssen R&D ʻIlelani | Hoʻopilikia i ka Renal|Ka maʻi Renal pae hope | Mei 2015 | Māhele 2 |
| NCT03169348 | Kulanui ʻo Assiut | ʻO ka maʻi hepa C | Nowemapa 1, 2017 | Pili ʻole |
| NCT02323594 | Bristol-Myers Squibb | Ma'i Hepatitis C | Kekemapa 2014 | Māhele 1 |
| NCT03537196 | Ke Kula Nui o Palani no ka Noi'i Ola a Lapa'au-Palani National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) | Hepatitis C|Hoʻohana lāʻau|Hepatitis C | Nowemapa 13, 2018 | Māhele 4 |
| NCT02103569 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | ʻApelila 2014 | Māhele 1 |
| NCT02772744 | Ke kula nui ʻo Zagazig|Kairo University | ʻO ka maʻi hepa C | Nowemapa 1, 2017 |
|
| NCT01718158 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Ianuali 2013 | Māhele 3 |
| NCT02496078 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | ʻAukake 2015 | Māhele 3 |
| NCT01425970 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Mei 2012 | Māhele 2 |
| NCT01471574 | Bristol-Myers Squibb | Hepatitis C, Genotype 1 | Kekemapa 2011 | Māhele 3 |
| NCT01573351 | Bristol-Myers Squibb | Hepatitis C Virus | Mei 2012 | Māhele 3 |
| NCT01938625 | ʻO Janssen R&D ʻIlelani | ʻO ka maʻi maʻi maʻi C, ka maʻi maʻi | Kekemapa 12, 2013 | Māhele 2 |
| NCT01492426 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Ianuali 2012 | Māhele 3 |
| NCT03480932 | Johns Hopkins Bloomberg School of Public Health|National Institute on Drug Abuse (NIDA)|YR Gaitonde Center for AIDS Research and Education | ʻO ka maʻi maʻi maʻi C, ka maʻi maʻi | Pepeluali 2, 2018 | Māhele 2|Mahele 3 |
| NCT03163849 | Kulanui ʻo Assiut | ʻO ka maʻi maʻi maʻi maʻi maʻi c | Sepatemaba 1, 2019 | Māhele 3 |
| NCT01581203 | Bristol-Myers Squibb | Hepatitis C Virus | Mei 2012 | Māhele 3 |
| NCT01492504 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Pepeluali 7, 2012 |
|
| NCT03686722 | Mohamed Raslan|Ke Kulanui ʻo Ain Shams|Ke Keʻena ʻImi Lapaʻau, Kairo, ʻAigupita | ʻO ka maʻi maʻi maʻi, ʻano 2|hepatitis C|ka hoʻopili ʻana i nā lāʻau | Kepakemapa 9, 2017 | Māhele 1 |
| NCT02262728 | Janssen Research & Development, LLC | ʻO ka maʻi maʻi maʻi C, ka maʻi maʻi | Kepakemapa 30, 2014 | Māhele 2 |
| NCT02349048 | Janssen Research & Development, LLC | Hepatitis C Virus | Ianuali 2015 | Māhele 2 |
| NCT03882307 | Kulanui ʻo Assiut | ʻO ka maʻi maʻi maʻi C, ka maʻi maʻi | Mei 2020 | Māhele mua 1 |
| NCT02758509 | Parc de Salut Mar | Hepatitis C|Cirrhosis | Ianuali 1, 2010 |
|
| NCT01795911 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Malaki 2013 | Māhele 2 |
| NCT03549832 | Ke Kulanui ʻo Assiut|Ke Kulanui o Sohag|Ke Kulanui o South Valley | HCV Coinfection | Ianuali 1, 2018 | Pili ʻole |
| NCT02161939 | Bristol-Myers Squibb | Hepatitis C |
| |
| NCT01309932 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Malaki 2011 | Māhele 2 |
| NCT01995266 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Pepeluali 28, 2014 | Māhele 3 |
| NCT02640157 | AbbVie | Ma'i Hepatitis C|Ma'i Hepatitis C|Ma'i Hepatitis C Genotype 3 | Kekemapa 2015 | Māhele 3 |
| NCT02032875 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Malaki 2014 | Māhele 3 |
| NCT02624063 | Ke Kulanui Federal o São Paulo | ʻO ka maʻi maʻi maʻi C, ka maʻi maʻi | Kekemapa 2015 | Māhele 4 |
| NCT00546715 | Bristol-Myers Squibb | Hepatitis C | Nowemapa 2007 | Māhele 1|Mahele 2 |
| NCT01718145 | Bristol-Myers Squibb | Ma'i Hepatitis C | Nowemapa 2012 | Māhele 3 |
| NCT01616524 | Bristol-Myers Squibb | Hepatitis C Virus (HCV) | Iulai 2012 | Māhele 3 |
| NCT02032901 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Ianuali 2014 | Māhele 3 |
| NCT03540212 | Ke Kulanui ʻo Ain Shams | Ka ma'i HCV mau | Kekemapa 10, 2017 | Māhele 2|Mahele 3 |
| NCT02097966 | Bristol-Myers Squibb | Hepatitis C |
| |
| NCT02596880 | Teheran University of Medical Sciences | Hepatitis C|Cirrhosis | Kepakemapa 2015 | Māhele 3 |
| NCT04019717 | ʻO Atea Pharmaceuticals, Inc. | ʻO ka maʻi maʻi maʻi C|Ka maʻi maʻi maʻi C, ka maʻi maʻi|ka maʻi hepatitis C | Iune 20, 2019 | Māhele 2 |
| NCT02992457 | Kulanui ʻo Tanta | ʻO ka maʻi hepa C | Ianuali 2015 | Māhele 4 |
| NCT03547895 | Kulanui ʻo Zagazig | Decompensated Cirrhosis | Iune 1, 2015 | Pili ʻole |
| NCT03004625 | Kaohsiung Medical University Chung-Ho Memorial Hospital|Chang Gung Memorial Hospital|National Taiwan University Hospital|Taipei Veterans General Hospital, Taiwan|China Medical University Hospital|National Cheng-Kung University Hospital | ʻO ka maʻi hepa C | Nowemapa 2016 | Māhele 3 |
| NCT01051414 | Bristol-Myers Squibb | Ma'i Hepatitis C | ʻApelila 2010 | Māhele 2 |
| NCT02309450 | ʻO ke Keʻena Lapaʻau Palani no ka Noʻonoʻo Ola a me ka ʻImi Lapaʻau-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | Hepatitis C Virus Genotype 4 Infection | Kekemapa 2014 | Māhele 2 |
| NCT01628692 | Bristol-Myers Squibb|Janssen Research & Development, LLC | Hepatitis C Virus | Iulai 2012 | Māhele 2 |
| NCT03186313 | ʻO ka Halemaʻi Liver o ʻAigupita|Wadi El Nil Hospital | ʻO ka maʻi hepa C | Kepakemapa 2016 | Māhele 3 |
| NCT03063723 | Halemaʻi Hoʻohui ʻekolu, Ke Kulanui ʻo Sun Yat-Sen | ʻO ka Hepatitis C (Maʻi ʻino) | Ianuali 1, 2016 |
|
| NCT00983957 | Bristol-Myers Squibb | Hepatitis C | ʻOkakopa 2009 | Māhele 1 |
| NCT01725542 | ʻO ke Keʻena Lapaʻau Palani no ka Noʻonoʻo Ola a me ka ʻImi Lapaʻau-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | HCV-HIV Hui-hui | Kekemapa 2012 | Māhele 2 |
| NCT02282709 | Kahua no ka ʻImi ʻĀpaʻa | Hepatitis C | Pepeluali 2014 | Māhele 3 |
| NCT02032888 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Pepeluali 2014 | Māhele 3 |
| NCT03247296 | Kulanui MTI | ʻO ka maʻi hepa C | Pepeluali 28, 2017 |
|
| NCT01389323 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Kepakemapa 2011 | Māhele 3 |
| NCT02556086 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Kekemapa 2015 | Māhele 2 |
| NCT01741545 | Bristol-Myers Squibb | Hepatitis C Virus | Malaki 31, 2013 | Māhele 3 |
| NCT01866930 | Bristol-Myers Squibb | Ma'i Hepatitis C mau | Iulai 11, 2013 | Māhele 3 |
| NCT02268864 | Janssen-Cilag International NV | ʻO ka maʻi maʻi maʻi C, ka maʻi maʻi | Ianuali 2015 | Māhele 2 |
| NCT01797848 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Iune 2014 | Māhele 3 |
| NCT03166280 | Eman Sayed Hassan Abd Allah|Assiut University | ʻO ka maʻi hepa C | Iune 2017 |
|
| NCT02159352 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Iune 2014 | Māhele 1 |
| NCT01125189 | Bristol-Myers Squibb | Hepatitis C Virus | Iulai 2010 | Māhele 2 |
| NCT03748745 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Pilikia laau | Nowemapa 19, 2018 | Māhele 1 |
| NCT01012895 | Bristol-Myers Squibb | Hepatitis C | Kekemapa 2009 | Māhele 2 |
| NCT02565888 | Ke Kulanui ʻo Radboud | Hepatitis C|HIV | Nowemapa 2015 | Māhele 1 |
| NCT02555943 | Ke Keʻena Noiʻi Kanaka a Ola Ola|Beijing 302 Halemai|Hakapila ʻo Nanfang o ke Kulanui Lapaʻau Hema | ʻO ka maʻi maʻi maʻi maʻi maʻi C|ka maʻi maʻi HBV| | Pepeluali 2015 | Māhele 2|Mahele 3 |
| NCT02304159 | Tarek I. Hassanein, MD, FACP, FAG, AGAF|Ke kikowaena noiʻi o Kaleponi Hema | Hepatitis C|Cirrhosis | Ianuali 2015 | Māhele 4 |
| NCT02580474 | Myeong Jun Song|Bristol-Myers Squibb|Soonchunhyang University Hospital|Dankook University|Chungnam National University Hospital|Konyang University Hospital|Eulji University Hospital|Saint Vincent's Hospital, Korea|Konkuk University Hospital|Cheongju St. Mary's Hospital, Cheongju , Korea|Hakapila ʻo Severance|Hakapila Guro University Korea|Hakapila Nui ʻo Eulji|Ke Kulanui Katolika o Korea | ʻO ka maʻi hepa C | Pepeluali 2016 | Māhele 4 |
| NCT02104843 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | ʻApelila 2014 | Māhele 1 |
| NCT01428063 | Bristol-Myers Squibb | Ma'i Hepatitis C | Kepakemapa 2011 | Māhele 2 |
| NCT02123654 | Bristol-Myers Squibb | Ma'i Hepatitis C | ʻApelila 2014 | Māhele 3 |
| NCT02565862 | Ke Kulanui ʻo Radboud | Hepatitis C|Diabetes Mellitus|Ke kū'ē i ka insulin | Ianuali 2016 | Māhele 1 |
| NCT04211844 | Ke Kulanui ʻo Ain Shams | Hepatitis C | ʻOkakopa 1, 2019 |
|
| NCT00874770 | Bristol-Myers Squibb | Ma'i Hepatitis C | Iune 2009 | Māhele 2 |
| NCT03883698 | Sanjay Gandhi Postgraduate Institute of Medical Sciences | ʻAʻole i ka maʻi maʻi, maʻi maʻi|hepatitis C | Malaki 15, 2019 | Māhele 3 |
| NCT01448044 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Kekemapa 2011 | Māhele 3 |
| NCT01359644 | Bristol-Myers Squibb|Pharmasset | Hepatitis C | Iune 2011 | Māhele 2 |
| NCT01842451 | Vertex Pharmaceuticals Incorporated | Hepatitis C|CHC|HCV|Hepatitis C | Iune 2013 | Māhele 2 |
| NCT02762448 | Halema'i Kaona o Tainan | Hepatitis c | Iulai 2016 |
|
| NCT02473211 | Ke Keena Imi Kanaka a Ola Ola|Beijing 302 Hospital | Ma'i Hepatitis C mau | Ianuali 2015 | Māhele 2|Mahele 3 |
| NCT01455090 | Bristol-Myers Squibb | Hepatitis C | Nowemapa 30, 2011 | Māhele 2 |
| NCT03490097 | Ke Kulanui ʻo Ain Shams | ʻO ka maʻi Hepatitis c|Metabolic Syndrome | Kekemapa 1, 2017 | Māhele 2|Mahele 3 |
| NCT01170962 | Bristol-Myers Squibb | Hepatitis C Virus | ʻAukake 2010 | Māhele 2 |
| NCT02333292 | Halemai Kula Nui o Valme|Hospital del SAS de Jerez|Hospital General Universitario Elche|Hospital La Línea de la Concepción|Complexo Hospitalario Universitario de A Coruña|Hospital de Figueres|Hospital Universitario Puerto Real|Hospital Universitario Virgen de la Victoria|Hospital Universitario de Canarias Halemai Nui Universitario de Alicante|Hakapila Universitario Araba|Hospital Royo Vilanova|Hospital Universitario de Burgos|Complejo Hospitalario Universitario de Huelva|Hospital Universitario Reina Sofia de Cordoba|Hospital Universitario Virgen Macarena|Complexo Hospitalario Universitario de Vigo|Clinica Universidad|Universidad de Navarra, Universidad de Navarra. Cecilio|Hospital Universitario La Fe|Hospital General Universitario de Valencia|Hospital Universitario Infanta Leonor|Hospital Universitario de Gran Canaria|Hospital General Universitario Santa Lucía|Centro Penitenciario Alicante 1|Hospital Regional Universitario Carlos Haya|Hospital Virgen de la Luz de Castellón|Paka Halemai Tauli, Sabadell | Ma'i Hepatitis C mau | Kekemapa 2014 |
|
| NCT03200184 | Teheran University of Medical Sciences | ʻO ka maʻi hepa C | Kepakemapa 1, 2016 | Māhele 4 |
| NCT03188276 | Halemaʻi Hoʻohui ʻekolu, Ke Kulanui ʻo Sun Yat-Sen | Hepatitis C | Pepeluali 1, 2016 | Māhele mua 1 |
| NCT01830205 | Bristol-Myers Squibb | ʻO ka maʻi hepa C | Kepakemapa 2012 | Māhele 1 |
Manaʻo18Nā papahana Loiloi Kūlike Kūlike i ʻae ʻia4, a6apono ʻia nā papahana.
Ua hoʻokumu ka ʻōnaehana hoʻokele maikaʻi honua kiʻekiʻe i ke kumu kūʻai.
Holo ka nānā ʻana i ka maikaʻi ma ke ola holoʻokoʻa o ka huahana e hōʻoia i ka maikaʻi a me ka hopena therapeutic.
Kākoʻo ka hui ʻoihana Regulatory Affairs i nā koi maikaʻi i ka wā o ke noi a me ke kākau inoa ʻana.
Kolea Countec Bottled Packaging Line
ʻO Taiwan CVC Bottled Packaging Line
Italia CAM Board Packaging Line
Mekini Fette Compacting German
ʻO Iapana Viswill Tablet ʻIke
Keena Mana o DCS
Ka launa pū ʻana o ka honua
ʻO ka launa pū ʻana o ka home
E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou
